Disease landscape

Cholangiocarcinoma clinical trials

Get alerts when Cholangiocarcinoma trials change

441 active trials 255 recruiting 36 Phase 3 254 sponsors 64 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 47 of 64 changes on 19 trials

2026-08-18
Recruitment suspended
Recruitment suspended: Pending protocol amendment
NCT05791448 AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver… · University of Southern California · Phase 1
2026-08-12
Primary completion pushed: 2025-06-30 → 2026-12-30
Sponsor changed: Evopoint Biosciences Inc. → Astellas Pharma Global Development, Inc.
Enrollment closed, study ongoing
Completion pushed: 2025-12-31 → 2027-06-30
NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. · Astellas Pharma Global Development, Inc. · Phase 1/2
2026-07-30
Primary completion pushed: 2026-08-11 → 2026-11-17
Completion moved earlier: 2027-09-30 → 2027-06-28
NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 · AstraZeneca · Phase 2
2026-08-06
Primary completion pushed: 2026-05 → 2027-06
Primary endpoint(s) modified
Completion pushed: 2026-05 → 2027-06
Trial arms changed: 17 → 18
NCT04999761 AB122 Platform Study · Taiho Pharmaceutical Co., Ltd. · Phase 1
2026-08-05
Primary completion pushed: 2026-07 → 2027-09
Completion pushed: 2026-07 → 2027-09
Trial arms changed: 9 → 10
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With… · AbbVie · Phase 1
2026-08-21
Primary completion pushed: 2026-01-15 → 2027-01-15
Completion pushed: 2026-01-15 → 2027-02-15
NCT06453590 Treatment of Distal Malignant Biliary Obstruction by Uncovered, Partially Covered, or… · Region Stockholm
2026-08-18
Primary completion pushed: 2026-07 → 2026-12
NCT06048133 Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced… · Nataliya Uboha · Phase 2
2026-08-07
Primary completion pushed: 2025-12-31 → 2026-08-12
Primary endpoint(s) modified
Enrollment reduced: 100 → 61 participants
Enrollment closed, study ongoing
Completion pushed: 2026-07-01 → 2027-12-07
NCT07159204 Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer · Peking Union Medical College Hospital · Phase 2
2026-08-01
Enrollment reduced: 117 → 31 participants
Enrollment closed, study ongoing
Trial sites reduced: 18 → 14 locations
NCT06921928 Study for AZD4360 in Participants With Advanced Solid Tumours · AstraZeneca · Phase 1/2
2026-08-14
Enrollment reduced: 88 → 4 participants
Primary completion moved earlier: 2026-09-30 → 2026-01-20
Completion pushed: 2026-09-30 → 2027-08-10
NCT05211323 A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy… · National Cancer Institute (NCI) · Phase 2
2026-08-20
Enrollment reduced: 24 → 18 participants
Trial completed
Primary completion moved earlier: 2026-05 → 2025-11-17
Completion moved earlier: 2026-05 → 2025-11-17
NCT05220046 Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced… · University of Nebraska · Phase 1
2026-08-25
Enrollment reopened
NCT06084481 Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With… · AbbVie · Phase 1
2026-08-26
Enrollment closed, study ongoing
Primary completion moved earlier: 2027-12 → 2026-09
NCT04510740 Liver Cancer Registry Platform · iOMEDICO AG
2026-08-01
Enrollment closed, study ongoing
Enrollment increased: 220 → 299 participants
NCT05876754 An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or… · Servier Affaires Médicales · Phase 3
2026-08-26
Recruitment opened
NCT06923475 Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab… · Amsterdam UMC, location VUmc · Phase 2/3
2026-08-25
Trial completed
Primary completion moved earlier: 2027-12-31 → 2026-08-06
Completion moved earlier: 2027-12-31 → 2026-08-06
NCT04145141 National Translational Science Network of Precision-based Immunotherapy for Primary Liver… · National Cancer Institute (NCI)
2026-08-14
Enrollment closed, study ongoing
NCT06399757 A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors · Apollo Therapeutics Ltd · Phase 1/2
2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT05823311 Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment… · Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 3
2026-08-09
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University → Second Affiliated Hospital, Zhejiang University, School of Medicine
NCT05532059 Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced… · Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2
2026-08-06
Enrollment closed, study ongoing
Trial sites reduced: 17 → 11 locations
NCT07021066 Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects… · SystImmune Inc. · Phase 1

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-26 NCT07786766 Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2… Haitao Zhao, MD new Phase 2
2026-08-24 NCT07780838 Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for the… Ohio State University Comprehensive Cancer Center new Phase 2
2026-08-17 NCT07768085 Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT Shengjing Hospital new
2026-08-14 NCT07766187 Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic… University of Wisconsin, Madison new Phase 2
2026-08-14 NCT07765433 Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the… ECOG-ACRIN Cancer Research Group new Phase 2/3
2026-08-12 NCT07760038 Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury Second Affiliated Hospital, Zhejiang University, School of Medicine new
2026-07-31 NCT07738939 IKS04 Regimen in Advanced Solid Tumors That Express CA242 Iksuda Therapeutics Ltd. new Phase 1
2026-07-23 NCT07723534 Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic… Midhun Malla new Phase 2
2026-07-20 NCT07714538 Breath Research Narrow Validation for Gastrointestinal Cancer Detection Imperial College London new
2026-07-17 NCT07710885 Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Taiho Pharmaceutical Co., Ltd. new Phase 3

Active trials by phase

Early Phase 1
4
Phase 1
46
Phase 1/2
36
Phase 2
168
Phase 2/3
13
Phase 3
23
Phase 4
4
Not charted: 147 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 441

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07486713 Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Rigel Pharmaceuticals Recruiting 2026-08-11
NCT05551299 Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic… University of Leipzig Recruiting 2025-03-27
NCT07619235 A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination… Xianglin Yuan Not Yet Recruiting 2026-06-01
NCT06818773 Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer Eastern Hepatobiliary Surgery Hospital Not Yet Recruiting 2025-02-10
Phase 3
NCT07221253 A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of… AstraZeneca Recruiting 2026-08-21
NCT06467357 Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary… AstraZeneca Recruiting 2026-08-19
NCT06622057 D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced… InnoPharmax Inc. Recruiting 2026-07-30
NCT07582315 A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally… Sichuan Baili Pharmaceutical Co., Ltd. Recruiting 2026-07-24
NCT07606599 A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With… Sichuan Baili Pharmaceutical Co., Ltd. Recruiting 2026-07-24
NCT07710885 Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer Taiho Pharmaceutical Co., Ltd. Recruiting 2026-07-17
NCT06282575 Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care… Jazz Pharmaceuticals Recruiting 2026-07-14
NCT07265674 A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B)… J-Pharma Co., Ltd. Recruiting 2026-07-01
NCT07229625 A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing… Suzhou Suncadia Biopharmaceuticals Co., Ltd. Recruiting 2026-01-28
NCT07155525 Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas Minia University Recruiting 2025-09-18
NCT07062263 Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced… Tata Memorial Centre Recruiting 2025-07-14
NCT05342194 Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of… Shanghai Junshi Bioscience Co., Ltd. Recruiting 2025-04-23
NCT05823311 Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment… Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting 2025-02-10
NCT07745296 Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer UNICANCER Not Yet Recruiting 2026-08-04
NCT05876754 An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or… Servier Affaires Médicales Active, Not Recruiting 2026-07-31
NCT05771480 Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary… AstraZeneca Active, Not Recruiting 2026-07-29
NCT07691515 Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus… Zhejiang Cancer Hospital Not Yet Recruiting 2026-07-14
NCT06109779 Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection… AstraZeneca Active, Not Recruiting 2026-07-10
NCT05948475 Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in… TransThera Sciences (Nanjing), Inc. Active, Not Recruiting 2026-07-06
NCT06591520 AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced… Akeso Active, Not Recruiting 2026-01-21
NCT07328919 Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients… TransThera Sciences (Nanjing), Inc. Not Yet Recruiting 2026-01-09
See all 441 active Cholangiocarcinoma trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (16) · Shanghai Zhongshan Hospital (13) · Fudan University (12) · Tianjin Medical University Cancer Institute and Hospital (12) · AstraZeneca (8) · M.D. Anderson Cancer Center (8) · Second Affiliated Hospital, School of Medicine, Zhejiang University (7) · Mayo Clinic (6) · Peking Union Medical College Hospital (6) · West China Hospital (6)

Get alerts when Cholangiocarcinoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free